ZVRA
Zevra Therapeutics Inc.
NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY
$10.17
+5.17% today
Updated 2026-04-30
Market cap
$585.24M
P/E ratio
7.33
P/S ratio
5.50x
EPS (TTM)
$1.35
Dividend yield
—
52W range
$7 – $13
Volume
1.1M
Zevra Therapeutics Inc. (ZVRA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
78.20%
Operating margin
27.30%
ROE
85.70%
ROA
-1.14%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-70416.00 | — | — | — |
| 2013 | — | $-5.23M | — | — | — |
| 2014 | — | $-24.45M | — | — | — |
| 2015 | — | $-54.66M | — | — | — |
| 2016 | — | $-16.52M | — | — | — |
| 2017 | — | $-43.39M | — | — | — |
| 2018 | — | $-56.47M | — | — | — |
| 2019 | $12.84M | $-24.52M | 77.06% | -158.40% | -191.00% |
| 2020 | $13.29M | $-12.76M | 90.18% | -42.21% | -96.03% |
| 2021 | $28.65M | $-8.55M | 92.81% | 26.98% | -29.86% |
| 2022 | $10.16M | $-26.77M | 97.82% | -418.91% | -263.48% |
| 2023 | $27.46M | $-46.05M | 89.28% | -180.63% | -167.69% |
| 2024 | $23.61M | $-105.51M | 68.59% | -368.47% | -446.85% |
| 2025 | $106.47M | $83.23M | 84.52% | -3.98% | 78.17% |